Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · bullishMedium impact
Esc
MetLife headquarters reflecting Piper Sandler analyst upgrade to Overweight with $110 price target
Photo: Investing.com

MetLife Stock Rises 1.4% on Piper Sandler Overweight Upgrade

Investing.com2 min read5 sources

Why is MetLife stock up today?

MetLife (MET) stock rose 1.4% on Wednesday after Piper Sandler upgraded it to Overweight and raised its price target to $110 from $99, arguing the insurer's years-long overhaul is undervalued.

Key numbers

MET stock price (Sep 23)~$97.25+1.4% today
Piper Sandler price target$110raised from $99
Piper Sandler valuation multiple10x earningsfrom 9x
Adjusted ROE (Q2 2026)17%top of 15–17% target range
Holding-company free cash flow (FY2025)$4.9B+6.5% vs FY2024's $4.6B
MET YTD performance+23%vs +4.3% for PRU

What happened

MetLife (MET) stock rose 1.4% on Wednesday after Piper Sandler upgraded it to Overweight and raised its price target to $110 from $99, arguing the insurer's years-long overhaul is undervalued. Piper Sandler also lifted its valuation multiple for MetLife from nine times earnings to ten times — a shift analysts use to signal that a company deserves to trade alongside better-regarded peers. The firm pointed to $4.9 billion in annual free cash flow and return on equity hitting 17 percent — the top of MetLife's own target range — as proof of the six-year transformation. At Wednesday's price of about $97, MetLife still trades below the new $110 target, leaving a potential gap of roughly 13 percent.

Why it matters

MetLife stock has already gained about 23 percent this year, yet Piper Sandler says the market still prices it as a middling insurer rather than the premium one it argues MetLife has become. Life insurers earn most of their profit by investing policyholders' premiums over long periods, so a sustained 17-percent return on equity signals the business is working efficiently — the kind of proof that draws investors willing to pay more for each dollar of earnings. The upgrade suggests MetLife's six-year transformation is finally earning broader Wall Street recognition.

Who this affects

Marketbullish
Medium impact
MET leads large-cap life insurers higher on upgrade news.
Companybullish
Medium impact
MetLife shareholders gain as analyst raises target to $110.
Competitorsneutral
Low impact
Rivals PRU and PFG face re-rating valuation comparison pressure.
Industrybullish
Low impact
Life insurance sector re-rating narrative gains analytical credibility.

MetLife vs Prudential, Unum, Principal Financial

MetLifeMET~$61.8B+1.4%+23%~9.1x
Prudential FinancialPRU$40.6B+0.1%+4.3%9.8x
Principal FinancialPFG$24.5B+0.7%+29.7%—
Unum GroupUNM$15.0B+1.3%+22.3%—

As of 2026-09-23

How we got here

  1. MetLife New Frontier Investor Day — $25B cumulative free cash flow target through 2029 announced.

  2. FY2024 results: adjusted ROE 15.2%, $4.6B free cash flow; $21B returned to shareholders since 2020.

  3. Evercore ISI downgrades MET to In Line from Outperform, cuts price target to $97 (per).

  4. Q2 2026 results: ROE hits 17% ceiling; MetLife board authorizes new $3B share buyback.

  5. Piper Sandler upgrades MET to Overweight from Neutral; raises price target to $110 from $99.

What to watch

  • Q3 2026 earnings — watch for ROE holding at or above 17% target.Q4 2026
  • Other analyst upgrades following Piper Sandler — consensus shift potential.Q4 2026
  • Federal Reserve rate path — higher rates boost life insurer investment income.Q4 2026

Educational content only. Not investment advice.

More briefsAll briefs →